Shaanxi Kanghui Pharm Co Ltd (603139) - Total Assets

Latest as of March 2026: CN¥1.71 Billion CNY ≈ $249.51 Million USD

Based on the latest financial reports, Shaanxi Kanghui Pharm Co Ltd (603139) holds total assets worth CN¥1.71 Billion CNY (≈ $249.51 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Shaanxi Kanghui Pharm Co Ltd - Total Assets Trend (2012–2025)

This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Shaanxi Kanghui Pharm Co Ltd stock valuation for the company's overall valuation and market capitalisation.

Shaanxi Kanghui Pharm Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Shaanxi Kanghui Pharm Co Ltd's total assets of CN¥1.71 Billion consist of 32.5% current assets and 67.5% non-current assets. Review total liabilities of Shaanxi Kanghui Pharm Co Ltd to assess the company's total debt and financial obligations.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 5.9%
Accounts Receivable CN¥226.74 Million 12.5%
Inventory CN¥163.14 Million 9.0%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥86.29 Million 4.8%
Goodwill CN¥7.49 Million 0.4%

Asset Composition Trend (2012–2025)

This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 603139 stock price and chart for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Shaanxi Kanghui Pharm Co Ltd's current assets represent 32.5% of total assets in 2025, a decrease from 73.6% in 2012.
  • Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, down from 14.4% in 2012.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 12.0% in 2012.
  • Asset Diversification: The largest asset category is accounts receivable at 12.5% of total assets.

Shaanxi Kanghui Pharm Co Ltd Competitors by Total Assets

Key competitors of Shaanxi Kanghui Pharm Co Ltd based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr81.26 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
China CN¥12.75 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.01 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Piramal Pharma Limited
NSE:PPLPHARMA
India Rs179.65 Billion
Harbin Gloria Pharmaceuticals
SHE:002437
China CN¥3.14 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion

Shaanxi Kanghui Pharm Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.63 0.95 5.59
Quick Ratio 0.41 0.67 4.74
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥-329.06 Million CN¥-32.98 Million CN¥666.05 Million

Shaanxi Kanghui Pharm Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shaanxi Kanghui Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 6.46
Latest Market Cap to Assets Ratio 0.31
Asset Growth Rate (YoY) -3.9%
Total Assets CN¥1.81 Billion
Market Capitalization $554.37 Million USD

Valuation Analysis

Below Book Valuation: The market values Shaanxi Kanghui Pharm Co Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Shaanxi Kanghui Pharm Co Ltd's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Shaanxi Kanghui Pharm Co Ltd (2012–2025)

The table below shows the annual total assets of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025.

Year Total Assets Change
2025-12-31 CN¥1.81 Billion
≈ $265.51 Million
-3.89%
2024-12-31 CN¥1.89 Billion
≈ $276.25 Million
-7.99%
2023-12-31 CN¥2.05 Billion
≈ $300.23 Million
+12.63%
2022-12-31 CN¥1.82 Billion
≈ $266.57 Million
-2.07%
2021-12-31 CN¥1.86 Billion
≈ $272.21 Million
+41.87%
2020-12-31 CN¥1.31 Billion
≈ $191.87 Million
+15.97%
2019-12-31 CN¥1.13 Billion
≈ $165.45 Million
+1.85%
2018-12-31 CN¥1.11 Billion
≈ $162.46 Million
+7.60%
2017-12-31 CN¥1.03 Billion
≈ $150.99 Million
+57.54%
2016-12-31 CN¥654.97 Million
≈ $95.84 Million
+13.24%
2015-12-31 CN¥578.40 Million
≈ $84.64 Million
+13.94%
2014-12-31 CN¥507.65 Million
≈ $74.28 Million
+12.81%
2013-12-31 CN¥450.00 Million
≈ $65.85 Million
+42.52%
2012-12-31 CN¥315.74 Million
≈ $46.20 Million
--

About Shaanxi Kanghui Pharm Co Ltd

SHG:603139 China Drug Manufacturers - Specialty & Generic
Market Cap
$554.37 Million
CN¥3.79 Billion CNY
Market Cap Rank
#11816 Global
#3388 in China
Share Price
CN¥37.93
Change (1 day)
-3.02%
52-Week Range
CN¥20.27 - CN¥45.21
All Time High
CN¥45.21
About

Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more